Resveratrol does not ameliorate muscle wasting in different types of cancer cachexia models.
OBJECTIVE
Resveratrol has been reported to have antitumoural effects and recently it has been demonstrated that resveratrol partially blocks skeletal muscle wasting by interfering with NF-kappaB activation. We decided to investigate the potential anti-wasting properties of resveratrol on different models of cancer cachexia in experimental animals.


RESULTS
Incubations of isolated extensor digitorum longus muscles in the presence of 30 microM of resveratrol caused a significant decrease in the rate of protein degradation. However, administration of resveratrol in vivo to both rats bearing the Yoshida AH-130 ascites hepatoma (at the dose of 1 mg/kg body weight) and mice bearing the Lewis lung carcinoma (at two different doses, 5 and 25 mg/kg body weight) had no effect on skeletal muscle mass or body weight in tumour-bearing rodents. In addition, a combination of resveratrol (3 mg/kg body weight) and fish oil was also unable to induce any changes in skeletal muscle weights.


CONCLUSIONS
It is therefore concluded from this study that resveratrol is unable to influence muscle mass in vivo and has no potential role as anticachectic agent for the treatment of muscle wasting associated with tumour growth.
Busquets
Sílvia
S
Departament de Bioquímica i Biologia Molecular, Universitat de Barcelona, Diagonal 645, 08028 Barcelona, Spain.
Fuster
Gemma
G
Ametller
Elisabet
E
Olivan
Mireia
M
Figueras
Maite
M
Costelli
Paola
P
Carbó
Neus
N
Argilés
Josep M
JM
López-Soriano
Francisco J
FJ
D000818:Animals; D001835:Body Weight / Q000187:drug effects / Q000502:physiology; D002100:Cachexia / Q000188:drug therapy* / Q000378:metabolism; D018827:Carcinoma, Lewis Lung; D004195:Disease Models, Animal; D002149:Energy Intake / Q000187:drug effects / Q000502:physiology; D005395:Fish Oils; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009124:Muscle Proteins / Q000378:metabolism*; D018482:Muscle, Skeletal / Q000187:drug effects* / Q000378:metabolism; D016328:NF-kappa B / Q000037:antagonists & inhibitors; D009374:Neoplasms, Experimental / Q000378:metabolism*; D009929:Organ Size / Q000187:drug effects; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D000077185:Resveratrol; D012517:Sarcoma, Yoshida; D013267:Stilbenes / Q000494:pharmacology*
D005395:Fish Oils; D009124:Muscle Proteins; D016328:NF-kappa B; D013267:Stilbenes; D000077185:Resveratrol